BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) (Q113919586)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) |
clinical trial |
Statements
A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin (NKTR-214) Combined With Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients With Metastatic or Recurrent HNSCC With PD-L1 Expressing Tumors (English)
0 references
9 March 2022
0 references
22 April 2022
0 references
2
0 references
18 year
0 references